Cardiac output improvement by pecavaptan: a novel dual‐acting vasopressin V1a/V2 receptor antagonist in experimental heart failure-Reference-Cited by-同舟云学术

Cardiac output improvement by pecavaptan: a novel dual‐acting vasopressin V1a/V2 receptor antagonist in experimental heart failure

Published:2020-10-09 Issue:5 Volume:23 Page:743-750
ISSN:1388-9842
Container-title:European Journal of Heart Failure
language:en
Short-container-title:Eur J Heart Fail

Author:

Mondritzki Thomas¹²,Mai Thuy Anh²,Vogel Julia²³,Pook Elisabeth¹,Wasnaire Pierre¹,Schmeck Carsten¹,Hüser Jörg¹,Dinh Wilfried¹²⁴,Truebel Hubert¹²,Kolkhof Peter¹

Affiliation:

1. Bayer AG Wuppertal Germany

2. University of Witten/Herdecke Witten Germany

3. University of Duisburg‐Essen Essen Germany

4. Department of Cardiology, HELIOS Clinic Wuppertal University Hospital Witten/Herdecke Wuppertal Germany

Funder

Bayer

Publisher

Wiley

Subject

Cardiology and Cardiovascular Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ejhf.2001

Reference22 articles.

1. Congestion in Acute Heart Failure Syndromes: An Essential Target of Evaluation and Treatment

2. The vulnerable phase after hospitalization for heart failure

3. Loop Diuretics in Acute Decompensated Heart Failure

4. Vasopressin Antagonism in Heart Failure

5. Tolvaptan, a Selective Oral Vasopressin V2-Receptor Antagonist, for Hyponatremia

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Diuretic Treatment in Heart Failure: A Practical Guide for Clinicians;Journal of Clinical Medicine;2024-07-30

2. Pharmacological properties and underlying mechanisms of aurantio‑obtusin (Review);Experimental and Therapeutic Medicine;2023-06-26

3. Vasopressin receptor antagonists: a patent summary (2018-2022);Expert Opinion on Therapeutic Patents;2023-05-04

4. Advanced heart failure: from definitions to therapeutic options;European Heart Journal Supplements;2023-04-26

5. Manejo multidisciplinario y terapia paliativa en falla cardiaca avanzada, revisión de la evidencia;Acta Bioclínica;2023